Table 1. Characteristics of included studies.
First Author | Year | Country of population | Sample size | Histology | Stage | First- antibody | Neutrophils location | Cut-off criteria | Cut-off value | Follow-up time | Hazard ratios | Survival analysis |
Rosario Alberto Caruso | 2002 | Italy | 273 | Gastric | Ib- IV | - (HE) | Intratumoral | Mean | >10cells/20HPF | NM | Reporta | OS |
Frede Donskov | 2006 | Denmark | 85 | RCC | NM | CD66b | Intratumoral | Median | 0 cells/mm2 | Median:57m(32–73 m) | Reporta, Authora | OS |
Hanne Krogh Jensen | 2009 | Denmark | 121 | RCC | I-IV | CD66b | Intratumoral | Median | 0 cells/HPF | Median:124 m (74–194 m) | Reporta+b+c, Authora | RFS, OS, CSS |
Sokratis Trellakis | 2010 | Germany | 40 | HNC | III -IV | CD66b | Intratumoral | NM | Low: −,+; High: ++,+++ | Median:69 m (43–124m) | SR a | OS |
Dong-Ming Kuang | 2010 | China | 200 | HCC | I-III | CD15 | Intratumoral, Peritumoral, Stromal | Median | Intratumoral:4; Peritumoral:54; Stromal:10 | NM | SRa+d, Survival curvea+d | DFS, OS |
Yi-Wei Li | 2011 | China | 281 | HCC | I-III | CD66b | Intratumoral Peritumoral | Fixed | Intratumoral:70%, Peritumoral:50% | Median:29 m (1.5–83m) | Reporta+c, Survival curvea+c | RFS, OS |
Lih-Chyang Chen | 2012 | China | 140 | HNC | NM | - (HE) | Intratumoral | Mean | 10 neutrophils/ 100 epithelial cells | NM | Survival curvec | RFS |
Qiang Gao | 2012 | China | 240 | HCC | NM | CD66b | Intratumoral | Median | 12 cells/ mm2 | NM | Reportc | RFS |
Fang-Ming Gu | 2012 | China | 123 | ICC | I/II/IIIa/ IIIc | CD66b | Intratumoral, Peritumoral | Median | 86 cells/ mm2 | Median:13m (4–111m) | Reporta | OS |
Marius Ilie | 2011 | France | 632 | NSCLC | I – III | CD66b | Intratumoral | Median | 49 cells/mm2 | Median:30m (0–112 m) | Survival curvea | OS |
Trine O. Jensen | 2011 | Denmark | 186 | Melanoma | I/II | CD66b | Intratumoral | Fixed | 0 cells/2 HPF | Median:12.2y (10.4–14.2 y) | Reporta+b+c | RFS,OS, CSS |
Hui-Lan Rao | 2012 | China | 229 | CRC | I-IV | CD66b | Intratumoral | Mean | 60 per TMA spot | Average:55.4m Median:60.0m (0.5–98 m) | Reporta, Survival curvea | OS |
CH Richards | 2012 | UK | 130 | CRC | NM | - (HE) | Peritumoral | Median | High: score 2–3, Low: score 0–1 | Median:105m (55–163m) | DEb | CSS |
Jing-jing Zhao | 2012 | China | 115 | Gastric | I-IV | CD15 | Intratumoral | Median | 21.60 cells/HPF | NM | Reporta | OS |
Shao-Lai Zhou | 2012 | China | 323 | HCC | NM | CD66b | Intratumoral | NM | Hgih, Low | NM | Reporta+c | OS, RFS |
Andreas Carus | 2013 | Denmark | 101 | CC | IB-IIA | CD66b | Intratumoral, Peritumoral, Stromal | Median | Intratumoral:23.2cells/mm2, Peritumoral:53.1cells/mm2, Stromal:28.3cells/ mm 2 | NM | Authorc, Reportc | RFS |
Andreas Carus | 2013 | Denmark | 335 | NSCLC | I–IIIA | CD66b | Intratumoral, Peritumoral, Stromal | Median | Intratumoral:8.7cells/mm2, Stromal:21.0 cells/ mm2 | NM | Authora+c | OS, RFS |
Claudia A. Dumitru | 2013 | Germany | 97 | HNC | NM | CD66b | Intratumoral | Median | NM | NM | Survival curvea | OS |
Claudia A. Dumitru | 2013 | Germany | 83 | HNC | I-IV | CD66b | Intratumoral | NM | High: medium and strong, Low: negative, weak | NM | Reporta | OS |
Y Ino | 2013 | Japan | 212 | PDC | NM | CD66b | Intratumoral | Median | NM | Median:18.8m (2.6–201m) | Reporta+d | OS, DFS |
Abbreviations: Gastric: gastric carcinoma; RCC: renal cell carcinoma; HNC: head and neck carcinoma; HCC: hepatocellular carcinoma; ICC: intrahepatic cholangiocarcinoma; NSCLC: non-small-cell lung cancer; CRC: colorectal carcinomas; CC: cervical cancer; PDC: pancreatic ductal carcinoma; HE: hematoxylin-eosin staining; OS: overall survival; CSS: cancer-specific survival; RFS: recurrence-free survival; DFS: disease-free survival; NM: not mentioned; a: OS; b: CSS; c: RFS; d: DFS; m: months; y: years; DE: data extrapolated; SR: systematic review [36].